SRC/YES1 Kinase Inhibitor NXP900 clinical trials
Also written NXP900.
How each study uses SRC/YES1 Kinase Inhibitor NXP900 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SRC/YES1 Kinase Inhibitor NXP900 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NXP900
- 3
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Nuvectis Pharma, Inc. (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test SRC/YES1 Kinase Inhibitor NXP900.
- Dec 2026Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerPhase 1 · Nuvectis Pharma, Inc.
- Mar 2027A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersPhase 1 · Nuvectis Pharma, Inc.
- Aug 2027Study of NXP900 With Lorlatinib in ALK+ Lung CancerPhase 1 · Nuvectis Pharma, Inc.
Studies
Open first, then newest update. How each study uses SRC/YES1 Kinase Inhibitor NXP900 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of NXP900 With Lorlatinib in ALK+ Lung CancerRecruitingPhase 1Nuvectis Pharma, Inc.NCT07784959Written as NXP900
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerRecruitingPhase 1Nuvectis Pharma, Inc.NCT07315113Written as NXP900
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersActive, not recruitingPhase 1Nuvectis Pharma, Inc.NCT05873686Written as NXP900